Nkarta Inc. (NKTX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter and year ended March 31, 2025.
Nkarta (NKTX) Upgraded to Buy: Here's Why
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nkarta to Participate in an April Investor Conference
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
Nkarta: Grinding Lower, Trying To Find Support
Nkarta, Inc. has provided significant pipeline updates, showcasing promising advancements in their innovative cell therapy treatments. A financial overview highlights a robust balance sheet, with sufficient cash reserves to support ongoing research and development activities. Strengths include cutting-edge technology and strategic partnerships, while risks involve clinical trial uncertainties and regulatory hurdles.
Nkarta: Betting On The Turnaround
Nkarta's NKX019 shows promise in treating autoimmune diseases, despite a 70% stock drop; strategic restructuring extends financial runway to 2029. Q4 and full-year 2024 earnings reveal significant R&D expenses and a net loss, but a strong cash position of $380.5M. Upcoming clinical data from Ntrust-1 and Ntrust-2 trials are key catalysts; positive results could validate NKX019 and attract investor attention.
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?
Nkarta, Inc. NKTX reported a fourth-quarter earnings report on Wednesday with a loss of 35 cents per share, beating the consensus of a loss of 41 cents.
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestones Cash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2024.
Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Nkarta (NKTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Nkarta (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Nkarta to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences:
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts
